Bellevue Group Ag Argenx Se Transaction History

Bellevue Group Ag

  • $4.31 Billion
  • Q1 2025

A detailed history of Bellevue Group Ag transactions in Argenx Se stock. As of the latest transaction made, Bellevue Group Ag holds 578,874 shares of ARGX stock, worth $319 Million. This represents 7.95% of its overall portfolio holdings.

Number of Shares
578,874
Previous 593,184 2.41%
Holding current value
$319 Million
Previous $365 Million 6.08%
% of portfolio
7.95%
Previous 7.27%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025
SELL
$571.0 - $671.75 $8.17 Million - $9.61 Million
-14,310 Reduced 2.41%
578,874 $343 Million
Q4 2024

Feb 14, 2025
SELL
$520.52 - $638.33 $20.6 Million - $25.3 Million
-39,645 Reduced 6.26%
593,184 $365 Million
Q3 2024

Nov 14, 2024
SELL
$434.22 - $551.9 $25.6 Million - $32.6 Million
-59,045 Reduced 8.53%
632,829 $343 Million
Q2 2024

Aug 14, 2024
SELL
$356.01 - $451.55 $42.4 Million - $53.8 Million
-119,142 Reduced 14.69%
691,874 $298 Million
Q1 2024

May 15, 2024
SELL
$356.95 - $413.29 $20.8 Million - $24.1 Million
-58,192 Reduced 6.69%
811,016 $319 Million
Q4 2023

Feb 14, 2024
SELL
$338.91 - $506.01 $14.3 Million - $21.4 Million
-42,322 Reduced 4.64%
869,208 $331 Million
Q3 2023

Nov 14, 2023
SELL
$369.35 - $548.43 $4.34 Million - $6.45 Million
-11,754 Reduced 1.27%
911,530 $448 Million
Q2 2023

Aug 14, 2023
BUY
$360.14 - $422.58 $13.1 Million - $15.4 Million
36,356 Added 4.1%
923,284 $360 Million
Q1 2023

May 15, 2023
SELL
$334.23 - $403.65 $8.08 Million - $9.76 Million
-24,172 Reduced 2.65%
886,928 $330 Million
Q4 2022

Feb 14, 2023
SELL
$342.17 - $402.31 $2.82 Million - $3.32 Million
-8,246 Reduced 0.9%
911,100 $345 Million
Q3 2022

Nov 14, 2022
SELL
$343.2 - $395.75 $4.96 Million - $5.72 Million
-14,457 Reduced 1.55%
919,346 $332 Million
Q2 2022

Aug 11, 2022
SELL
$269.58 - $378.88 $5.24 Million - $7.36 Million
-19,435 Reduced 2.04%
933,803 $350 Million
Q1 2022

May 13, 2022
SELL
$254.45 - $351.06 $11.1 Million - $15.4 Million
-43,800 Reduced 4.39%
953,238 $301 Million
Q4 2021

Feb 10, 2022
BUY
$272.01 - $353.03 $3.56 Million - $4.62 Million
13,100 Added 1.33%
997,038 $349 Million
Q3 2021

Nov 12, 2021
BUY
$295.0 - $350.58 $2.92 Million - $3.47 Million
9,900 Added 1.02%
983,938 $297 Million
Q2 2021

Aug 12, 2021
BUY
$257.11 - $319.92 $5.01 Million - $6.23 Million
19,484 Added 2.04%
974,038 $293 Million
Q1 2021

May 12, 2021
BUY
$268.3 - $380.31 $2.47 Million - $3.5 Million
9,206 Added 0.97%
954,554 $263 Million
Q4 2020

Feb 16, 2021
SELL
$248.13 - $308.36 $3.39 Million - $4.21 Million
-13,668 Reduced 1.43%
945,348 $278 Million
Q3 2020

Nov 16, 2020
BUY
$215.51 - $272.51 $1.08 Million - $1.36 Million
5,000 Added 0.52%
959,016 $252 Million
Q2 2020

Aug 13, 2020
SELL
$127.44 - $232.72 $2.61 Million - $4.77 Million
-20,488 Reduced 2.1%
954,016 $215 Million
Q1 2020

May 14, 2020
BUY
$108.83 - $165.23 $709,027 - $1.08 Million
6,515 Added 0.67%
974,504 $128 Million
Q4 2019

Feb 14, 2020
SELL
$106.59 - $164.21 $559,597 - $862,102
-5,250 Reduced 0.54%
967,989 $156 Million
Q3 2019

Nov 14, 2019
BUY
$113.31 - $150.51 $3.24 Million - $4.3 Million
28,600 Added 3.03%
973,239 $110 Million
Q2 2019

Aug 14, 2019
BUY
$115.0 - $141.58 $106 Million - $131 Million
924,739 Added 4646.93%
944,639 $134 Million
Q1 2019

May 15, 2019
BUY
$98.85 - $134.59 $721,605 - $982,507
7,300 Added 57.94%
19,900 $2.48 Million
Q4 2018

Feb 12, 2019
BUY
$63.81 - $109.82 $804,006 - $1.38 Million
12,600 New
12,600 $1.21 Million

Others Institutions Holding ARGX

# of Institutions
498
Shares Held
28.5M
Call Options Held
330K
Put Options Held
286K
View Full List

About ARGENX SE

ARGX Quotes by TradingView
  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $30.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email